Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.715 -0.235 (-12.05%)
Streaming Delayed Price Updated: 3:54 PM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
-6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy - 
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – 
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor – 
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus to Participate in Upcoming Investor Conferences
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.